0 4 Dual dual JJ 5 12 effects effect NNS 13 15 of of IN 16 19 LPS LPS NNP 20 30 antibodies antibody NNS 31 33 on on IN 34 42 cellular cellular JJ 43 49 uptake uptake NN 50 52 of of IN 53 56 LPS LPS NNP 57 60 and and CC 61 72 LPS-induced lps-induced JJ 73 88 proinflammatory proinflammatory JJ 89 98 functions function NNS 98 99 . . . 101 106 Human human JJ 107 117 phagocytes phagocyte NNS 118 127 recognize recognize VBP 128 137 bacterial bacterial JJ 138 141 LPS lps NN 142 143 ( ( ( 143 152 endotoxin endotoxin NN 152 153 ) ) ) 154 161 through through IN 162 170 membrane membrane NN 171 175 CD14 cd14 NN 176 177 ( ( ( 177 182 mCD14 mcd14 NN 182 183 ) ) ) 183 184 , , , 185 186 a a DT 187 202 proinflammatory proinflammatory JJ 203 206 LPS LPS NNP 207 215 receptor receptor NN 215 216 . . . 217 221 This this DT 222 227 study study NN 228 234 tested test VBD 235 238 the the DT 239 249 hypothesis hypothesis NN 250 254 that that IN 255 263 anti-LPS anti-lps JJ 264 267 Abs ab NNS 268 278 neutralize neutralize VBP 279 288 endotoxin endotoxin NN 289 291 by by IN 292 300 blocking block VBG 301 309 cellular cellular JJ 310 316 uptake uptake NN 317 324 through through IN 325 330 mCD14 mcd14 NN 330 331 . . . 332 345 Ab-associated ab-associated JJ 346 353 changes change NNS 354 356 in in IN 357 360 the the DT 361 367 uptake uptake NN 368 371 and and CC 372 380 cellular cellular JJ 381 393 distribution distribution NN 394 396 of of IN 397 405 FITC-LPS FITC-LPS NNP 406 410 were be VBD 411 419 assessed assess VBN 420 422 by by IN 423 427 flow flow NN 428 437 cytometry cytometry NN 438 441 and and CC 442 447 laser laser NN 448 456 scanning scanning NN 457 465 confocal confocal JJ 466 476 microscopy microscopy NN 477 479 in in IN 480 485 human human JJ 486 502 CD14-transfected cd14-transfected JJ 503 510 Chinese chinese JJ 511 518 hamster hamster NN 519 524 ovary ovary NN 525 536 fibroblasts fibroblast NNS 537 538 ( ( ( 538 546 CHO-CD14 cho-cd14 NN 547 552 cells cell NNS 552 553 ) ) ) 554 557 and and CC 558 563 human human JJ 564 574 peripheral peripheral JJ 575 580 blood blood NN 581 590 monocytes monocyte NNS 590 591 . . . 592 595 LPS LPS NNP 596 601 core- core- NN 602 605 and and CC 606 612 O-side o-side JJ 613 627 chain-specific chain-specific JJ 628 632 mAbs mab NNS 633 642 inhibited inhibit VBD 643 657 mCD14-mediated mcd14-mediated JJ 658 661 LPS lps NN 662 668 uptake uptake NN 669 671 by by IN 672 676 both both DT 677 681 cell cell NN 682 687 types type NNS 688 690 in in IN 691 694 the the DT 695 703 presence presence NN 704 706 of of IN 707 712 serum serum NN 712 713 . . . 714 720 O-side o-side JJ 721 735 chain-specific chain-specific JJ 736 739 mAb mab NN 740 752 concurrently concurrently RB 753 761 enhanced enhance VBD 762 782 complement-dependent complement-dependent JJ 783 786 LPS lps NN 787 793 uptake uptake NN 794 796 by by IN 797 806 monocytes monocyte NNS 807 814 through through IN 815 825 complement complement NN 826 836 receptor-1 receptor-1 NN 837 838 ( ( ( 838 841 CR1 cr1 NN 841 842 ) ) ) 843 846 and and CC 847 853 uptake uptake NN 854 856 by by IN 857 865 CHO-CD14 cho-cd14 NN 866 871 cells cell NNS 872 881 involving involve VBG 882 889 another another DT 890 901 heat-labile heat-labile JJ 902 907 serum serum NN 908 917 factor(s) factor(s) NN 918 921 and and CC 922 937 cell-associated cell-associated JJ 938 949 recognition recognition NN 950 961 molecule(s) molecule(s) NN 961 962 . . . 963 976 Core-specific core-specific JJ 977 980 mAb mab NN 981 990 inhibited inhibit VBD 991 1005 mCD14-mediated mcd14-mediated JJ 1006 1012 uptake uptake NN 1013 1015 of of IN 1016 1026 homologous homologous JJ 1027 1030 and and CC 1031 1043 heterologous heterologous JJ 1044 1047 LPS lps NN 1047 1048 , , , 1049 1054 while while IN 1055 1064 producing produce VBG 1065 1069 less less RBR 1070 1080 concurrent concurrent JJ 1081 1092 enhancement enhancement NN 1093 1095 of of IN 1096 1114 non-mCD14-mediated non-mcd14-mediated JJ 1115 1118 LPS lps NN 1119 1125 uptake uptake NN 1125 1126 . . . 1127 1130 The the DT 1131 1141 modulation modulation NN 1142 1144 by by IN 1145 1153 anti-LPS anti-lps JJ 1154 1158 mAbs mab NNS 1159 1161 of of IN 1162 1176 mCD14-mediated mcd14-mediated JJ 1177 1180 LPS lps NN 1181 1187 uptake uptake NN 1188 1191 was be VBD 1192 1202 associated associate VBN 1203 1207 with with IN 1208 1218 inhibition inhibition NN 1219 1221 of of IN 1222 1233 LPS-induced lps-induced JJ 1234 1241 nuclear nuclear JJ 1242 1255 factor-kappaB factor-kappaB NNP 1256 1257 ( ( ( 1257 1266 NF-kappaB NF-kappaB NNP 1266 1267 ) ) ) 1268 1281 translocation translocation NN 1282 1285 and and CC 1286 1295 TNF-alpha TNF-alpha NNP 1296 1305 secretion secretion NN 1306 1308 in in IN 1309 1317 CHO-CD14 cho-cd14 NN 1318 1323 cells cell NNS 1324 1327 and and CC 1328 1337 monocytes monocyte NNS 1337 1338 , , , 1339 1351 respectively respectively RB 1351 1352 , , , 1353 1358 while while IN 1359 1362 mAb mab NN 1363 1374 enhancement enhancement NN 1375 1377 of of IN 1378 1396 non-mCD14-mediated non-mcd14-mediated JJ 1397 1400 LPS lps NN 1401 1407 uptake uptake NN 1408 1418 stimulated stimulate VBD 1419 1424 these these DT 1425 1435 activities activity NNS 1435 1436 . . . 1437 1449 LPS-specific lps-specific JJ 1450 1453 Abs ab NNS 1454 1458 thus thus RB 1459 1466 mediate mediate VBP 1467 1484 anti-inflammatory anti-inflammatory JJ 1485 1488 and and CC 1489 1504 proinflammatory proinflammatory JJ 1505 1514 functions function NNS 1514 1515 , , , 1516 1528 respectively respectively RB 1528 1529 , , , 1530 1532 by by IN 1533 1543 preventing prevent VBG 1544 1550 target target NN 1551 1555 cell cell NN 1556 1562 uptake uptake NN 1563 1565 of of IN 1566 1569 LPS lps NN 1570 1577 through through IN 1578 1583 mCD14 mcd14 NN 1584 1587 and and CC 1588 1598 augmenting augment VBG 1599 1605 uptake uptake NN 1606 1613 through through IN 1614 1617 CR1 cr1 NN 1618 1620 or or CC 1621 1626 other other JJ 1627 1631 cell cell NN 1632 1641 receptors receptor NNS 1641 1642 . . .